| Combination chemotherapy with docetaxel and cisplatin as first-line treatment in advanced gastric cancer: is it a new effective chemotherapy? |
|
Dong Bok Shin |
|
고려대학교 의과대학 내과학교실 |
| 논평 : 진행성 위암에 대한 1차 요법으로 Docetaxel과 Cisplatin 복합화학요법의 효과와 안정성에 대한 연구를 중심으로 |
|
신동복 |
|
|
|
|
|
|
| Abstract |
|
Advanced gastric carcinoma is associated with a poor prognosis. Although a number of combination chemotherapy regimens , usually based on 5FU and cisplatin, have been tested in randomized studies, there is no globally accepted standard therapy. Docetaxel is active against advanced gastric carcinoma and some investigators report a response rate ranging from 18% to 24% with a single-agent docetaxel.
Kim et al performed a phase II trial with docetaxel plus cisplatin(DC) in patients with untreated advanced gastric cancer, which resulted in a response rate(per protocol population) of 42.4% but a response rate for the intent-to-treatment analysis is only 33.3%. Granulocytopenia worse than grade 3 occurred only in 7.6% in spite of older patients being included. Non-hematologic toxicities were negligible.
The lower rate of hematologic and non-hematologic toxicities over a number of other studies is considered as clinically irrelevant. I would like to remind Dr Kim coutiously that he has to adress these discrepancies.(Korean J Med 72:577-579, 2007)
Key Words : Advanced gastric cancer, Docetaxel, Cisplatin |
| Key Words:
Advanced gastric cancer, Docetaxel, Cisplatin |
|
PDF Links
Full text via DOI
Download Citation
